Drugmakers Mallinckrodt and Endo get a bump from tariffs

Drugmakers Mallinckrodt and Endo get a bump from tariffs in $6.7 billion merger
Mallinckrodt and Endo , drugmakers which recently emerged from bankruptcy after a wave of U.S. opioid lawsuits, announced plans Thursday to join forces in a deal valued at $6.7 billion.
Mallinckrodt, Endo Merger to Create Diversified Pharmaceuticals Firm
Drugmaker Mallinckrodt struck a deal to buy Endo in an effort to build a diversified pharmaceuticals company with a hefty U.S. footprint.
Mallinckrodt and Endo plan merger as they look to recover from opioid litigation
The new entity will be listed on the New York Stock Exchange and is expected to generate pro forma revenue of $3.6 billion in 2025 and at least $150 million of annual operating synergies by year three.
Mallinckrodt and Endo Announce Merger to Build Diversified Pharmaceuticals Powerhouse
Pharmaceutical leaders Mallinckrodt plc and Endo, Inc. (OTCQX: NDOI) have entered an agreement to merge, creating a global, diversified company poised to deliver enhanced patient
Mallinckrodt and Endo sign $6.7bn merger deal
The two companies are merging after previously filing for bankruptcy due to opioid-related litigation and financial losses.
Mallinckrodt, Endo Merger To Create Pharma Entity Valued At $7 Billion
Mallinckrodt and Endo are merging in a $6.7 billion deal, with a pro forma NYSE listing and $900 million in financing.
Pharma Firms Mallinckrodt and Endo Agree to Merge in $6.7B Cash and Stock Deal
Mallinckrodt and Endo, pharmaceutical companies that have each encountered business struggles, announced Thursday a $6.7 billion merger that they contend will result in a combined entity with the ...
Drugmakers Mallinckrodt and Endo Are in Talks to Merge
Mallinckrodt Pharmaceuticals and Endo Inc. are exploring a potential merger that could be valued at about $7 billion, people with knowledge of the matter said.
Troubled Drugmakers Mallinckrodt, Endo Officially Announce $6.7B Merger
As per the Thursday release, Endo will be folded into Mallinckrodt, which will then continue as the holding entity for the combined companies. Post-merger, the company will be listed on the New York Stock Exchange and is projected to generate around $3.6 billion in revenue this year.
Drugmakers Mallinckrodt and Endo to merge in nearly $7 billion deal
Endo shareholders will get $80 million in cash and own 49.9% of the combined company, while Mallinckrodt shareholders will own the rest for an enterprise value of $6.7 billion, the companies said on Thursday.
Mallinckrodt Pharma, Endo Reach Deal for $6.7 Billion Merger
Mallinckrodt Pharmaceuticals and Endo Inc. plan to merge and create a $6.7 billion company in a move that will cut costs and broaden access to patients and new treatments.
Fierce Pharma4d
Mallinckrodt, Endo look to carve out brighter future through $6.7B merger
Mallinckrodt and Endo are merging in a cash and stock deal worth some $6.7 billion, the companies said Thursday. Under the ...
TMCnet3d
ENDO INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Endo, Inc. - NDOI
Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC ("KSF") are investigating the proposed merger of Endo, Inc. (OTC: NDOI) and Mallinckrodt plc.